A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6MG) or placebo for sleep disturbance and depressed mood

International Clinical Psychopharmacology

Volumn 25, Issue 3, 2010, Pages 132-142

  Serfaty, Marc Antony ^a,b   Osborne, Debbie ^a   Buszewicz, Marta J ^a   Blizard, Robert ^a   Raven, Peter W ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Southgate   (United Kingdom)

Author keywords

Major depressive disorder; Melatonin; Mood; Randomized controlled trial; Sleep

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; FLUOXETINE; MELATONIN; NEFAZODONE; PAROXETINE; PLACEBO; VENLAFAXINE;

ACTIMETRY; ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SLEEP TIME; SOMNOLENCE; TREATMENT DURATION; VIVID DREAM; WAKEFULNESS;

ADULT; ANTIDEPRESSIVE AGENTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MELATONIN; PLACEBOS; SLEEP DISORDERS;

EID: 77950958736     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32832c260b     Document Type: Article

References (72)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, (DSM-IV). 4th ed. Washington, DC: APA.
2. American Sleep Disorders Association (ASDA) (1990). ICSD-International Classification of Sleep Disorders: diagnostic and coding manual. Rochester, Minnesota: Diagnostic Classification Steering Committee
3. Thorpy MJ, Chairman. Arendt J (1995). Melatonin and the pineal gland. London: Chapman & Hall.
4. Arendt J (2006). Does melatonin improve sleep? BMJ 332:550.
5. Arendt J, Skene DJ (2005). Melatonin as a chronobiotic. Sleep Med Rev 9:25-39.
6. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961). An inventory for measuring depression. Arch Gen Psychiatry 4:561-571.
7. Becker P (2006). Treatment of sleep dysfunction and psychiatric disorders. Curr Treat Opin Neurol 8:367-375.
8. Bellipanni GFDIM, Blasi F, Di Marzo A (2005). Effects of melatonin in perimenopausal and menopausal women: our personal experience. Ann N Y Acad Sci 1057:393-402.
9. Benca RM, Obermeyer WH, Thisted RA, Gillin JC (1992). Sleep and psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 49:651-668.
10. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C (1999). Meta-analysis of dose-effect relatiohships in randomised clinical trials. Br J Psychiatry 174:297-303.
11. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, et al. (2005). Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9:41-50.
12. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, et al. (2006). Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332:385-388.
13. Cagnacci A, Krauchi K, Wirz-Justice A, Volpe A (1997). Homeostatic versus circadian effects of melatonin on core body temperature in humans. J Biol Rhythms 12:509-517.
14. Carman JS, Post RM, Buswell R, Goodwin FK (1976). Negative effects of melatonin on depression. Am J Psychiatry 133:1181-1186.
15. Checkley S (1989). The relationship between biological rhythms and the affective disorders. In: Arendt J, Minors DS, Waterhouse JM, editors. Biological rhythms in clinical practice. London: Wright. pp. 160-183.
16. Childs PA, Rodin I, Martin NJ, Plaskett L, Thompson C, Allen NHP, et al. (1995). Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls. B J Psychiatry 166:196-198.
17. Cole RJ, Kripke DF, Gruen W, Mullaney DJ, Gillin JC (1992). Automatic sleep/wake identification from wrist activity. Sleep 15:461-469.
18. Cotzias GC, Tang LC, Miller ST, Ginos JZ (1971). Melatonin and abnormal movements induced by L-dopa in mice. Science 173:450-454.
19. Crasson M, Kjiri S, Colin A, Kjiri K, L'Hermite-Baleriaux M, Ansseau M, et al. (2004). Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinology 29:1-12.
20. Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM (2000). Use of slow-release melatonin in treatment resistant depression. J Psychiatry Neurosci 25:48-52.
21. De Vries MW, Peeters FPML (1997). Melatonin as a therapeutic agent in the treatment of sleep disturbance in depression. J Nerv Ment Dis 185:201-202.
22. Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, et al. (2001). Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psych 62 (Suppl):30-33.
23. Dolberg OT, Hirschmann S, Grunhaus L (1998). Melatonin for the treatment of sleep disturbances in major depression. Am J Psychiatry 155:1119-1121.
24. Endicott J, Spitzer RL (1978). A diagnostic interview-the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837-844.
25. Fainstein I, Bonetto AJ, Brusco LI, Cardinali DP (1997). Effects of melatonin in elderly patients with sleep disturbance: a pilot study. Curr Ther Res 58:990-1000.
26. Frazer A, Brown R, Kocsis J, Amsterdam J, Winokur A, Sweeney J, et al. (1986). Patterns of melatonin rhythm in depression. J Neural Transm 21:269-290.
27. Gillin JC, Duncan W, Pettigrew KD, Frankel B, Snyder F (1979). Successful separation of depressed, normal, and insomniac subjects by EEG sleep data. Am J Psychiatry 36:85-90.
28. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg 23:56-62.
29. Hanoun N, Mocaer E, Boyer A, Hamon M, Lanfumey L (2004). Differential effects of the novel antidepressant agomelatine (S20098) versus fluoxetine on 5-HT-sub (1A) receptors in the rat brain. Neuropharmacol 47:515-526.
30. Herxeimer A, Petrie KJ (2005). Melatonin for the prevention and treatment of jet lag. The Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No: CD001520.DOI.1002/14651858.CD001520.
31. Kennedy SH, Emsley R (2006). Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 16:93-100.
32. Lam R (2007). High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder. Int Clin Psychophar-macol 22 (Suppl 2):S21-S25.
33. Leppamaki S, Partonen T, Vakkuri O, Lonnqvist J, Partinen M, Laudon M (2003). Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behaviour. Eur Neuropsychopharmacol 13:137-145.
34. Lewy AJ, Sack RL, Miller LS, Hoban TM (1987). Antidepressant and circadian phase-shifting effects of light. Science 235:352-354.
35. Lewy AJ, Bauer VK, Cutler NL, Sack RL (1997). Melatonin treatment of winter depression: a pilot study. Psychiatry Res 77:57-61.
36. Lewy AJ, Bauer VK, Ahmed S, Thomas KH, Cutler NL, Singer CM, et al. (1998). The human phase response curve (PRC) to melatonin is about 12h out of phase with the PRC to light. Chronobiol Int 15:71-83.
37. 10 Zeitgeber time 14: the therapeutic window for phase delayed winter depressives treated with melatonin. Chronobiol Int 20:1215-1216.
38. Lewy AJ, Leflwer BJ, Emens JS, Bauer V (2006). The circadian basis of winter depression. Proc Natl Acad Sci USA 103:7414-7419.
39. 2c antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17:239-247.
40. 2c receptor antagonist, in the treatment of major depressive disorders. Encaphale 29:165-171.
41. McIntyre IM, Judd FK, Marriott PM, Burrows GD, Norman TR (1989). Plasma melatonin levels in affective states. Int J Clin Pharmacol Res 9:159-164.
42. Moher D, Schulz KF, Altman D (2001). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285:1987-1991. (Pubitemid 32366951)
43. Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D (1995). Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ 310:441-445.
44. Olie JP, Emsley R (2005). Confirmed clinical efficacy of agomelatine (25-50 mg) in major depression: two randomized, double blind, placebo-controlled studies. Eur Neuropsychopharmacol 15:S416-S417.
45. Olie JP, Kasper S (2007). Efficacy of agomelatine, a MT. 1/MT. 2 receptor agonist with 5-HT. 2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharm 10:661-673.
46. Parrot AC, Hindmarsh I (1978). Factor analysis of sleep evaluation questionnaire. Psychol Med 8:325-329.
47. Parry BL, Fernando Martinez L, Maurer EL, Loopez A, Sorensen D, Meliska CJ (2006). Sleep, rhythms and women's mood. Part II. Menopause. Sleep Med Rev 10:197-208.
48. Perlis ML, Giles DE, Buysse DJ, Tu X, Kupfer DJ (1997). Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 42:209-212.
49. Pinto-Meza A, Fernandez A, Serrano-Blanco A, Haro JP (2008). Adequacy of antidepressant treatment in Spanish primary care: a naturalistic six-month follow-up study. Psychiatr Serv 59:78-83.
50. Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S (2007). Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology 190:575-579. (Pubitemid 46204474)
51. Quitkin FM, Stewart JW, McGrath PJ, Tricamo E, Rabkin JG, Ocepek-Welikson K, et al. (1993). Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 21 (Suppl):30-34.
52. Reppert SM, Weaver DR (1995). Melatonin madness. Cell 83:1059-1062.
53. Rosenthal NE, Sack DA, James SP, Parry BL, Mendelson WB, Tamarkin L, et al. (1985). Seasonal affective disorder and phototherapy. Ann NY Acad Sci 453:260-269.
54. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P (2005). Phase III study to determine the efficacy of ramelteon in elderly patients with chronic insomnia [Abstract]. Proceedings of new clinical drug evaluation unit; June 6-9, 2005, Boca Raton, Florida.
55. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P (2006). Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 7:312-318.
56. Sack RL, Brandes BS, Kendall BS, Lewy AJ (2000). Entrainment of free-running circadian rhythms by melatonin in blind people. New Eng J Med 343:1070-1077.
57. Sadeh A, Alster J, Urbach D, Lavie P (1989). Actigraphically based automatic bedtime sleep-wake scoring: validity and clinical applications. J Ambul Monit 2:209-216.
58. Sekula LK, Lucke JF, Heist EK, Czambel RK, Rubin RT (1997). Neuroendocrine aspects of primary endogenous depression XV: mathematical modeling of nocturnal melatonin secretion in major depressives and normal controls. Psychiatry Res 69:143-153.
59. Serfaty MA (2006). The use of melatonin for sleep disturbance in depression and dementia. MD Thesis, University of London.
60. Serfaty MA, Kennell-Webb S, Warner J, Blizard R, Raven P (2002). Double blind randomised placebo controlled trial of low dose melatonin for sleep disorder in dementia [abstract]. Int J Geriatric Psychiatry 17:1-8.
61. Serfaty MA, Osborne D, Buszewicz MJ, Raven PW (2003). The effect of exogeneous melatonin in major depression. Chronobiol Int 20:1191-1192.
62. Skene DJ, Deacon S, Arendt J (1996). Use of melatonin in circadian rhythm disorders and following phase shifts. Acta Neurobiol Exp 56:359-362.
63. Stanley N (1997). Actigraphy in psychopharmacology. In: Hindmarch I, Stonier PD, editors. Human psychopharmacology, measures and methods. Vol.6. Chichester: John Wiley.
64. Streiner DL (2002). The case of the missing data: methods of dealing with dropouts and other research vagaries. W CAN J Psychiatry 47:70-77.
65. Van Bemmel AL (1997). The link between sleep and depression: the effects of antidepressants on EEG sleep. J Psychosom Res 42:555-564.
66. Wetterberg L (1978). Melatonin in humans: physiological and clinical studies. J Neural Transm 13 (Suppl):389-410.
67. Wirz-Justice A (2006). Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol 21 (Suppl 1):S11-S15.
68. Wirz-Justice A, Graw P, Krauchi K, Gisin B, Arendt J, Aldhous M, et al. (1990). Morning or night time melatonin is ineffective in seasonal affective disorder. J Psychiatr Res 24:129-137.
69. Zeger SL, Liang KY (1986). The analysis of discrete and continuous longitudinal data. Biometrics 42:121-130.
70. Zhdanova IV (2005a). Melatonin as a hypnotic: pro. Sleep Med Rev 9:51-65.
71. Zhdanova IV (2005b). Melatonin as a hypnotic: con. Sleep Med Rev 9:81.
72. Zhdanova IV, Wurtman RJ, Regan M, Taylor JA, Shi JP, Leclair OU (2001). Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 86:4727-4730.